Entwicklungen in der Neurogenetik am Beispiel der Schizophrenie

Kernaussagen

• Die psychiatrische Forschung hat auf dem Gebiet der Genetik rasante Fortschritte gemacht.

• Methodische Neuentwicklungen haben zur Identifikation einer Reihe häufiger und seltener genetischer Risikofaktoren geführt und damit zur Klärung der Ätiologie dieser Erkrankungen wesentlich beigetragen.

• Potenziell der größte Gewinn, den die praktische Psychiatrie aus der genetisch-neurogenetischen Grundlagenforschung ziehen kann, sind Ansätze, Gene zum Ausgangspunkt einer translationalen Forschung zu machen, die zur Entwicklung mechanistisch neuer Therapieverfahren führt. Die geschilderten ersten Ansatzpunkte hierfür sind erfolgversprechend und geben Anlass zur Hoffnung, mithilfe gesicherter genetischer Daten schwere psychiatrische Erkrankungen finden zu können.

Publication History

Publication Date:
01 March 2010 (online)

• Literatur

• Sullivan PF, Kendler KS, Neale MC. Schizophrenia as a complex trait: evidence from a meta-analysis of twin studies.. Arch Gen Psychiatry 2003; 60: 1187-1192
• Sullivan PF, Neale MC, Kendler KS. Genetic epidemiology of major depression: review and meta-analysis.. Am J Psychiatry 2000; 157: 1552-1562
• McPherson JD, Marra M, Hillier L. et al. A physical map of the human genome.. Nature 2001; 409: 934-941
• International Hapmap Consortium. A haplotype map of the human genome.. Nature 2005; 437: 1299-1320
• Manolio TA, Brooks LD, Collins FS. A HapMap harvest of insights into the genetics of common disease.. The Journal of clinical investigation 2008; 118: 1590-1605
• O'Donovan MC, Craddock NJ, Owen MJ. Genetics of psychosis; insights from views across the genome.. Hum Genet 2009; 126: 3-12
• Purcell SM, Wray NR, Stone JL. et al. Common polygenic variation contributes to risk of schizophrenia and bipolar disorder.. Nature 2009; 460: 748-752
• Shi J, Levinson DF, Duan J. et al. Common variants on chromosome 6p22.1 are associated with schizophrenia.. Nature 2009; 460: 753-757
• Stefansson H, Ophoff RA, Steinberg S. et al. Common variants conferring risk of schizophrenia.. Nature 2009; 460: 744-747
• O'Donovan MC, Craddock N, Norton N. et al. Identification of loci associated with schizophrenia by genome-wide association and follow-up.. Nat Genet 2008; 40: 1053-1055
• Esslinger C, Walter H, Kirsch P. et al. Neural mechanisms of a genome-wide supported psychosis variant.. Science 2009; 324: 605
• Meyer-Lindenberg AS, Olsen RK, Kohn PD. et al. Regionally specific disturbance of dorsolateral prefrontal-hippocampal functional connectivity in schizophrenia.. Arch Gen Psychiatry 2005; 62: 379-386
• Redon R, Ishikawa S, Fitch KR. et al. Global variation in copy number in the human genome.. Nature 2006; 444: 444-454
• Stefansson H, Rujescu D, Cichon S. et al. Large recurrent microdeletions associated with schizophrenia.. Nature 2008; 455: 232-236
• Walsh T, McClellan JM, McCarthy SE. et al. Rare structural variants disrupt multiple genes in neurodevelopmental pathways in schizophrenia.. Science 2008; 320: 539-543
• International SchizophreniaConsortium” IS. Rare chromosomal deletions and duplications increase risk of schizophrenia.. Nature 2008; 455: 237-241
• Insel TR, Scolnick EM. Cure therapeutics and strategic prevention: raising the bar for mental health research.. Mol Psychiatry 2006; 11: 11-17
• Meyer-Lindenberg A, Kohn PD, Kolachana B. et al. Midbrain dopamine and prefrontal function in humans: interaction and modulation by COMT genotype.. Nat Neurosci 2005; 8: 594-596
• Apud JA, Mattay V, Chen J. et al. Tolcapone improves cognition and cortical information processing in normal human subjects.. Neuropsychopharmacology 2007; 32: 1011-1020
• Meyer-Lindenberg A, Weinberger DR. Intermediate phenotypes and genetic mechanisms of psychiatric disorders.. Nat Rev Neurosci 2006; 7: 818-827
• Huffaker SJ, Chen J, Nicodemus KK. et al. A primate-specific, brain isoform of KCNH2 affects cortical physiology, cognition, neuronal repolarization and risk of schizophrenia.. Nat Med 2009; 15: 509-518
• Patil ST, Zhang L, Martenyi F. et al. Activation of mGlu2 / 3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial.. Nat Med 2007; 13: 1102-1107
• Tan HY, Chen Q, Sust S. et al. Epistasis between catechol-O-methyltransferase and type II metabotropic glutamate receptor 3 genes on working memory brain function.. Proc Natl Acad Sci U S A 2007; 104: 12536-12541